Anthem Biosciences IPO: Massive Demand and Big Expectations

IPO fever has gripped investors with Anthem Biosciences launching its ₹3,395 crore public offering. The company, a Bengaluru-based player in the CRDMO space, is drawing attention from every corner of the market. Not every IPO manages to hit nearly 10 times oversubscription by its third day—Anthem just did, and that’s sending out a strong signal to anyone still on the fence.

The company opened its doors to investors from July 14 to July 16, 2025, setting a price band between ₹540 and ₹570 per share. All eyes are now on the listing date, July 21, when shares are scheduled to begin trading on the BSE and NSE at 10:00 AM. That’s not far off, and with the way things look, the debut could be electric.

What Makes Anthem Biosciences Stand Out?

Founded in 2006, Anthem Biosciences isn’t exactly a rookie. Its focus lies in research, development, and manufacturing for the pharma industry. In simple terms, Anthem helps with everything from discovering new drugs to mass-producing them. Whether it’s solid APIs (active pharmaceutical ingredients), high-tech biologics, or hard-to-make specialty ingredients, the firm offers a solution for almost every stage of drug development. Large pharmaceutical companies across the globe have relied on them to bring molecules from the lab bench all the way to a patient’s bedside.

This is an offer-for-sale (OFS) IPO, which means Anthem isn’t pocketing any fresh funds from the issue; the money heads straight to the shareholders selling their stakes. Still, that hasn’t dampened enthusiasm. Anchor investors such as Abu Dhabi Investment Authority and PineBridge Global Funds added a serious dose of confidence, committing a whopping ₹1,016 crore before retail applications even began. When names like these put their money on the table, it’s tough for retail investors not to take notice.

The buzz isn’t just from anchor support. On the day of the IPO opening, the grey market premium was signaling a 27% bump over the maximum price band. For anyone wondering what that means—if the grey market is right, shares could list at around ₹720. That’s a tempting prospect for anyone betting on listing day gains.

But it’s not just hype. When a public issue sees ten times more bids than available shares, it’s more than just market noise. Potential buyers have been lining up, and the final allotment is scheduled for July 17, followed by refunds and share credits on July 18. So if you’ve applied, watch for updates on your bank or broker app.

Of course, IPO investing comes with its fair share of risks, from market volatility to changes in sector trends. But Anthem’s track record in contract pharma, the involvement of heavyweight anchor investors, and the subscription frenzy all add up to a company in the spotlight this July. For those still keeping score, Anthem’s IPO is one of 2025’s biggest talking points so far—and with market signals this strong, it isn’t hard to see why.